NeuroOne Medical Technologies Corporation develops medical technology for surgical diagnosis and treatment of neurological disorders. The company’s platform centers on thin-film electrode technology used in recording, monitoring, mapping, ablation and brain stimulation applications, including Evo Cortical, Evo sEEG and the OneRF Ablation System.
NeuroOne news commonly covers FDA 510(k) clearances, product applications for epilepsy, facial pain and other neurosurgical uses, patent activity around neural probe and electrode technologies, financial results, capital raises, commercial orders, investor conferences and management updates. Coverage also reflects the company’s efforts to extend the OneRF platform into additional ablation, stimulation and drug-delivery applications.
NeuroOne (NMTC) entered a research and development subaward agreement with Dartmouth to advance neurotransmitter sensing technology toward potential human use. NeuroOne will receive approximately $200,000 through April 30, 2027, with additional funds expected during the following two years.
The Dartmouth-led team received an NIH grant of approximately $1 million for the first year through the NIH BRAIN Initiative. The collaboration includes the VA Medical Center and Beth Israel Deaconess Medical Center. It seeks to combine neurochemical sensing with NeuroOne’s sEEG electrodes, which record electrical activity in the brain, to monitor electrical and neurochemical signals in real time.
NeuroOne Medical Technologies (NMTC) expects preliminary fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% year over year. The quarter ended September 30, 2026, compares with approximately $2.7 million in fiscal fourth-quarter 2025. Expected full-year product revenue is approximately $10.5 million, up 15.6% and at the top of the prior $9.2 million–$10.5 million guidance range.
In September, NeuroOne secured a $4.5 million purchase order, its largest ever, and shipped approximately $1.0 million of it. Remaining shipments are expected to begin in fiscal first-quarter 2027 and continue into the second quarter, subject to manufacturing and delivery schedules. Open purchase orders for shipments through fiscal first-quarter 2027 reached $5.4 million as of September 30. Fiscal 2026 product orders increased 24.2%. The revenue figures are unaudited and subject to year-end accounting and audit adjustments.
NeuroOne (NMTC) entered a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System, expanding commercial access across key counties including the Los Angeles metropolitan area.
The deal advances the company’s strategy to build a U.S. distribution network for its minimally invasive radiofrequency solution for trigeminal neuralgia. The OneRF® system, cleared via FDA 510(k), is indicated for creating radiofrequency lesions to treat pain or lesion nerve tissue in functional neurosurgical procedures and is designed to streamline workflow with temperature-monitored ablation and a multi-contact probe enabling stimulation, mapping and ablation.
NeuroOne Medical Technologies (NASDAQ: NMTC), a medical technology company focused on neurological disorders, will participate in the Sidoti & Co. Virtual Small-Cap Conference on September 17-18, 2025. CEO Dave Rosa and CFO Ron McClurg will present on September 17th at 12:15 PM ET.
The company reported strong performance with Q3 FY2025 revenue increasing 105% to $1.7 million and improved gross margin of 53.9%. Notable achievements include FDA 510(k) Clearance for their OneRF® Trigeminal Nerve Ablation System for facial pain treatment. The company confirms funding through fiscal year 2026.
NeuroOne Medical Technologies (NASDAQ: NMTC) has received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System, designed to treat facial pain through radiofrequency lesioning. The system features a pioneering multi-contact RF probe that enables both precise localization and targeted ablation of pain-conducting nerve tissue.
The technology targets trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people annually in the United States. NeuroOne plans a limited commercial launch in Q4 2025, with potential revenue generation beginning in late 2025. The company aims to expand the OneRF® technology platform to address additional pain management applications, including lower back pain treatment.
NeuroOne Medical Technologies (NASDAQ: NMTC) reported strong Q3 FY2025 financial results, with product revenue surging 105% year-over-year to $1.7 million and gross margin expanding to 53.9%. The company successfully completed an oversubscribed $8.2 million capital raise, securing funding through FY2026.
Key operational highlights include the first OneRF® Ablation System patient achieving one-year seizure freedom, FDA submission for the OneRF® Trigeminal Nerve Ablation System, and receipt of the first order for their sEEG-based drug delivery system from a major biopharmaceutical company. The company strengthened its IP portfolio with 17 patents and received USPTO allowance for a key manufacturing patent.
NeuroOne maintains its FY2025 product revenue guidance of $8.0-$10.0 million, representing 132-190% growth, and increased gross margin expectations to 50-53%.
NeuroOne Medical Technologies (NASDAQ: NMTC), a medical technology company specializing in neurological disorder treatments, has scheduled its fiscal third quarter 2025 earnings release and conference call. The company will announce financial results for the quarter ended June 30, 2025, before market open on August 14, 2025.
Management will host an investor conference call and webcast at 8:30 a.m. Eastern Time to discuss quarterly results and provide a corporate update. The call will include a Q&A session for telephone participants, with replay access available until August 28, 2025.
NeuroOne Medical Technologies (Nasdaq: NMTC) has received a notice of allowance from the USPTO for a key patent titled "Methods for Making Probe Devices and Related Devices." The patent application (17/392,773) covers novel methods for manufacturing neural probe devices, including specific processes for probe component arrangement and electrode contact material deposition.
The company's intellectual property portfolio now encompasses 17 issued and pending patents across the U.S. and internationally, covering various thin-film electrode technologies. The patent is expected to be formally issued in the coming months, strengthening NeuroOne's position in neural and spinal cord electrode technology.